Highmount Capital’s Bristol-Myers Squibb BMY Stock Holding History

Highmount Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$2.12M	Buy	31,779 +160	+0.5%	+$10.5K	0.54%	47
2015 Q1	$2.04M	Sell	31,619 -494	-2%	-$30.9K	0.49%	47
2014 Q4	$1.9M	Sell	32,113 -1,030	-3%	-$58.1K	0.46%	53
2014 Q3	$1.7M	Buy	33,143 +1,510	+5%	+$75.4K	0.42%	55
2014 Q2	$1.53M	Buy	31,633 +1,285	+4%	+$63.3K	0.37%	60
2014 Q1	$1.58M	Sell	30,348 -60,078	-66%	-$3.2M	0.37%	60
2013 Q4	$4.81M	Buy	90,426 +347	+0.4%	+$17.7K	1.1%	22
2013 Q3	$4.17M	Buy	90,079 +3,288	+4%	+$144K	1.03%	25
2013 Q2	$3.88M	Buy	+86,791	New	+$3.77M	1.02%	25

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Highmount Capital's BMY Position: Q2 2015 in Review

Highmount Capital increased its Bristol-Myers Squibb (BMY) stake by 0.51% in Q2 2015, buying an estimated $10.5K and bringing the position to 31,779 shares worth $2.12M. The position accounts for 0.54% of the portfolio, ranked #47.

Highmount Capital first reported a position in BMY in Q2 2013 and has held it in 9 quarters since. The position peaked at $4.81M in Q4 2013. 1,448 funds tracked by Wall St. Rank hold BMY as of Q2 2015.

Highmount Capital held 31,779 shares of Bristol-Myers Squibb worth $2.12M as of Q2 2015.
Highmount Capital bought 160 Bristol-Myers Squibb shares in Q2 2015, an estimated $10.5K.
Bristol-Myers Squibb made up 0.54% of Highmount Capital's portfolio in Q2 2015, its #47 holding.
Highmount Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 9 quarters since.
Highmount Capital's Bristol-Myers Squibb position peaked at $4.81M in Q4 2013.
1,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2015.

Based on Highmount Capital's 13F filing for Q2 2015, filed 14 Aug 2015.